Our Leadership

AltruBio’ senior management is built on a team of individuals possessing strong academic knowledge, high-level managerial experience and scientific expertise in a range of fields including life science, pharmacology, healthcare and immunology.

Patrick Y. Yang, Ph.D.

Chairman of the Board

Dr. Pat Yang is Executive Chairman, AltruBio. In addition to serving on corporate boards, he also works as an independent consultant in the Biopharmaceutical industry.
Most recently, Dr. Yang worked at Juno Therapeutics in Seattleas Executive Vice President from September 2017 to January 2019.
Previously, Dr. Yang was Roche’s Global Head of Technical Operations in Switzerland from 2009 to 2013. In this role, he was responsible for Roche’s biopharmaceutical process development, engineering, quality, technical regulatory, supply chain and 21 manufacturing plants with approximately 15,000 employees around the world -- with an operating budget of $4.5 billion per year. He was previously executive vice president, Product Operations of Genentech, Inc. based in the San Francisco Bay area. Dr. Yang joined Genentech in 2003 as vice president, Manufacturing and Engineering, and was promoted to senior vice president, Product Operations, in December 2004, then to executive vice president in January 2006.
Prior to joining Genentech, Dr. Yang served for 11 years at Merck & Company in New Jersey in various leadership positions including vice president of Asia Pacific Operations and vice president of Global Supply Chain Management. Prior to joining Merck in 1992, Yang spent 12 years at General Electric, serving in several research, engineering, technology, and manufacturing leadership roles with increasing scope of responsibilities. Before GE, Dr. Yang spent five years in aerospace control systems research and development with Life Systems, Inc.
Dr. Yang holds a Bachelor of Science from the National Chiao Tung University in Taiwan, a Master of Science from the University of Cincinnati, and a doctorate in engineering from Ohio State University, Columbus, Ohio. Dr. Yang is a member of Board of Directors for three public companies: Codexis, Amyris, and PharmaEssentia. He also serves on the corporate boards of several private companies including Acepodia, Archigen Biotech, Sana Biotech, and Taiwania Capital Management. He previously served on the boards of two other public companies: Tesoro/Andeaver (2010-2018) and Celladon (2014-2016).

Sean P. Bohen, M.D., Ph.D.

Dr. Sean Bohen was executive vice president of global medicines development and chief medical officer at AstraZeneca from 2015 to 2019. He was responsible for AstraZeneca’s worldwide product development and clinical programs to address unmet medical needs and renew AstraZeneca's product pipeline. Prior to joining AstraZeneca, he was Senior Vice President of Genentech Early Development from January, 2011. Dr. Bohen’s career at Genentech spanned 12 years. He joined Genentech in 2003 as Assistant Medical Director, Rituxan Heme/Onc. He was Associate Medical Director of Oncology Exploratory Clinical Development in 2004 and became Medical Director in 2005, then Associate Director in April, 2006. In October, 2006, he was Director of ITGR Exploratory Clinical Development and was promoted to Senior Director in October, 2007, then to Vice President of Immunology Development in August, 2008. In addition, Dr. Bohen also was an Adjunct Clinical Instructor in Oncology at Stanford University School of Medicine from 2002 to 2011. He received his Bachelor of Science (Bacteriology) from University of Wisconsin-Madison, and M.D. and Ph.D. in Biochemistry from University of California, San Francisco.

Judy Chou, Ph.D.

President and Chief Executive Officer

With 25 years of experience in drug development and biomanufacturing, Dr. Judy Chou currently is the President, CEO, and Board member of AltruBio. Before joining the company, she headed the global Pharmaceutical Biotech organization at Bayer Pharmaceuticals overseeing the manufacturing and distribution of Bayer’s $3+ billion per year biotechnology product portfolio & 2000+ employees and leading the drug development activities for Biologics pipeline. In addition, she serves as the site head for Bayer’s facility in Berkeley, CA, USA. She is well recognized by the biomedical industry for her leadership and has received the Most Influential Women in Business Award in 2018.
Before Bayer, she held the role of Vice President of Pharmaceutical /Technical Operations at Pfizer, Inc., formerly Medivation, where she led the Development and Manufacturing organizations for both biologics and small molecule products. She was also Vice President of R&D at Tanvex Biopharma, Inc., where Dr. Chou led the development of rich pipeline projects in R&D, manufacturing, and clinical development & operations to enable the success of the company’s IPO. Throughout Dr. Chou’s career, she has achieved significant milestones in protein therapeutic development and multiple filings of BLAs, NDAs, and INDs of novel products and is recognized for her work at Genentech, Wyeth, and Abbott especially in the development of breakthrough technologies in analytical characterization and the accelerated product development.
Before joining the industry, Dr. Chou was a research faculty member at Harvard University Medical School, focused on cell biology and neuroscience research. Dr. Chou obtained her Ph.D. from Yale University and completed her post-doctoral training at Max-Planck Institute in Germany.

John Doyle

John Doyle was chief executive officer and a member of the board of directors at Castlight Health, a publicly held healthcare IT firm, from 2017 to 2019. John joined Castlight in 2012 as its chief financial officer and held that role through the Company’s initial public offering. He was later named chief operating officer and then president of the Company in 2016. Prior to joining Castlight, John was chief operating officer of Achaogen, Inc., a biotechnology company focused on the development of antibiotics for the treatment of life-threatening infections. He joined Achaogen in 2009 and also served as chief financial officer in addition to his role as COO. Upon leaving Achaogen to join Castlight in 2012, John was named to the board of Achaogen where he served until 2019. As a member of the Achaogen board, John served at various times as chairperson of the compensation committee and as a member of the nominating and governance committee. Prior to joining Achaogen, John was vice president of corporate finance and business planning at Genentech from 2007 until 2009 when Genentech became a wholly owned subsidiary of Roche. Prior to Genentech, John spent more than 15 years primarily in the biotechnology industry where he had most recently been the senior vice president of corporate development and chief financial officer of Renovis, a publicly held biotechnology firm. John holds an MBA from the University of California, Berkeley, and received his undergraduate degree from California Polytechnic State University, San Luis Obispo. He is a member of the 2012 Class of Henry Crown Fellows at the Aspen Institute.

STEPHEN G. JUELSGAARD, D.V.M., J.D.

Stephen (“Steve”) Juelsgaard, is a former executive vice president, secretary and chief compliance officer of Genentech, Inc. He reported to Genentech’s CEO and was responsible for Genentech’s Corporate Law, Intellectual Property, Government Affairs (Federal and State), Human Resources, and Healthcare Compliance groups, as well as the Business Services group, which included Strategic Facilities Planning, Corporate Security, Business Continuity, and Environment, Health & Safety. He also chaired Genentech’s Capital Governance Committee, which oversaw major capital expenditures at the company and was a member of Genentech’s Executive Committee, the most senior management committee at the company. He served as secretary to Genentech’s Board of Directors and each of the Board’s Committees from 1997 to 2009. Dr. Juelsgaard’s career at Genentech spanned 24 years. He joined Genentech in 1985 as corporate counsel and became senior corporate counsel in 1989. In 1992 he became vice president, Corporate Law and in 1994 was named general counsel, a role he served in through 2007. He was named a senior vice president in 1998. In 2002, he was appointed executive vice president and in 2005 was named chief compliance officer. He was the company’s representative on the board of directors of the California Healthcare Institute from 2005 until 2009. He left Genentech in 2009 when it became a wholly owned subsidiary of Roche. Prior to joining Genentech, he was an associate for three years with the law firm Wilson Sonsini Goodrich & Rosati in Palo Alto, California. Prior to attending law school, he was engaged for three years in a private veterinary medical (equine) practice in Southern California. He is a member of the Independent Citizens Oversight Committee (board of directors) of the California Institute for Regenerative Medicine where he also is the chairman of the ICOC’s Intellectual Property and Industry Subcommittee and serves on the Application Review, Science Finance and Evaluation Subcommittees. He is a past member of the board of directors of Ivivi Health Sciences LLC, a private medical device company, and of Rio Grande Neurosciences, Inc., a private company engaged in the development of pulsed electromagnetic field technology as well as transcranial electrical stimulation and transcranial magnetic stimulation technologies. Dr. Juelsgaard received his Doctor of Veterinary Medicine degree from Iowa State University in 1972 and a Masters degree in Veterinary Clinical Sciences in 1975 from Iowa State University where his research was focused on immunology. In 1982 he received a law degree from Stanford Law School.

Corsee Sanders, Ph.D.

Corsee D. Sanders, Ph.D., was most recently the Strategic Advisor to the Celgene Office of the Chief Medical Officer. She was on the Executive Committee of Juno Therapeutics from January 2017 up to its acquisition by Celgene in 2018, reporting to the CEO and accountable for Quantitative Sciences, Project Leadership, Development Operations, and CAR T Patient Operations. Prior to Juno, Dr. Sanders spent 7 years with Roche Pharmaceuticals in various roles, including Global Head of Biometrics, Global Head of Clinical Operations, and Global Head of Industry Collaborations. She was a member of the Late Stage Portfolio Committee, Co-chair of the Roche-Chugai Joint Portfolio Management Committee, and Vice-chair of the Board of Directors of TransCelerate Inc., on behalf of Roche. She spent 15 years with Genentech, Inc., prior to its acquisition by Roche, leading functions including Clinical and Nonclinical Biostatistics, Health Economics, Epidemiology, Real World Evidence, Business and Data Operations. Prior to that, she was a Biostatistics leader with Schering-Plough in NJ, and Centocor, Inc. in Malvern, PA. She started her career as a statistician with the Technical Board for Agricultural Credit, an arm of the Presidential Committee on Agricultural Credit in the Philippines. Dr. Sanders holds Bachelor and Master of Science degrees in statistics from the University of the Philippines and a Ph.D. in Statistics from the Wharton Doctoral Programs of the University of Pennsylvania. Dr. Sanders is a member of the Board of Trustees at Fred Hutchinson Cancer Research Center and a board director of Molecular Templates.

Judy Chou, Ph.D.

President and Chief Executive Officer

With 25 years of experience in drug development and biomanufacturing, Dr. Judy Chou currently is the President, CEO, and Board member of AltruBio. Before joining the company, she headed the global Pharmaceutical Biotech organization at Bayer Pharmaceuticals overseeing the manufacturing and distribution of Bayer’s $3+ billion per year biotechnology product portfolio & 2000+ employees and leading the drug development activities for Biologics pipeline. In addition, she serves as the site head for Bayer’s facility in Berkeley, CA, USA. She is well recognized by the biomedical industry for her leadership and has received the Most Influential Women in Business Award in 2018.
Before Bayer, she held the role of Vice President of Pharmaceutical /Technical Operations at Pfizer, Inc., formerly Medivation, where she led the Development and Manufacturing organizations for both biologics and small molecule products. She was also Vice President of R&D at Tanvex Biopharma, Inc., where Dr. Chou led the development of rich pipeline projects in R&D, manufacturing, and clinical development & operations to enable the success of the company’s IPO. Throughout Dr. Chou’s career, she has achieved significant milestones in protein therapeutic development and multiple filings of BLAs, NDAs, and INDs of novel products and is recognized for her work at Genentech, Wyeth, and Abbott especially in the development of breakthrough technologies in analytical characterization and the accelerated product development.
Before joining the industry, Dr. Chou was a research faculty member at Harvard University Medical School, focused on cell biology and neuroscience research. Dr. Chou obtained her Ph.D. from Yale University and completed her post-doctoral training at Max-Planck Institute in Germany.

Shih-Yao Lin, MD., Ph.D.

President of AltruBio Taiwan R&D Center, and
Head of Clinical Development, AltruBio Inc.

Prior to joining AltruBio, Dr. Lin was a research fellow (1998-2004) at Laboratory of Allergy and Immunology, Department of Experimental Pathology, Beth Israel Deaconess Medical Center in Boston, USA. Dr. Lin received his MD degree from School of Medicine, National Taiwan University, and completed the resident training at the Department of Laboratory Medicine, National Taiwan University Hospital. He also received the PhD degree (Immunology) from Centre d'Immunologie de Marseille-Luminy, University of Aix-Marseille II in Marseille, France.

Joseph S. McCracken, DVM, MS

Head of Business Development

Joe McCracken currently advises biopharmaceutical companies on the design and implementation of corporate strategy and business development initiatives; and serves on the Boards of Alkahest, Inc., EdiGENE Corporation, Kindred Biosciences, Regimmune Inc., and Savara Pharmaceuticals. Dr. McCracken was previously Vice President and Global Head of Business Development & Licensing for Roche Pharma, where he was responsible for Roche Pharma’s global in-licensing and out-licensing activities. From October 2009 until July 2011 he was General Manager, Roche Pharma Japan & Asia Regional Head, Roche Partnering. Prior to joining Roche Pharma, Dr. McCracken held the position of Vice President, Business Development at Genentech for 10 years, and previously held similar positions at Aventis Pharma and Rhone-Poulenc Rorer. Dr. McCracken holds a Bachelor of Science in Microbiology, a Master of Science in Pharmacology and a Doctorate in Veterinary Medicine from The Ohio State University.

David T. Rubin, MD, AGAF, FACG, FASGE, FACP

Joseph B. Kirsner Professor of Medicine

Professor Rubin is a renowned gastroenterologist who specializes in the treatment and assessment of digestive diseases. He is the Joseph B. Kirsner Professor of Medicine at the University of Chicago, where he is also Chief of the Section of Gastroenterology, Hepatology and Nutrition, and co-director of the Digestive Diseases Center. His clinical expertise includes inflammatory bowel diseases (Crohn’s disease and ulcerative colitis) and high-risk cancer syndromes.
Dr. Rubin received his Doctor of Medicine degree from the Pritzker School of Medicine, and did his residency and fellowship work at the University of Chicago. He also completed a fellowship at the University of Chicago MacLean Center for Clinical Medical Ethics.

Anthony W. Tolcher, M.D., FRCPC, FACP

Dr. Tolcher is a leading expert in the development of new anticancer agents, especially molecular genetic targets as well as immune-oncology agents. He is the CEO, co-founder and director of clinical research at NEXT ONCOLOGY in San Antonio, Texas, a phase I program with the mission to accelerate the development of the next breakthrough cure for cancer through high quality Phase I clinical and clinical pharmacology trials.
In 2007 Dr. Tolcher co-founded and for a decade served as director of clinical research at South Texas Accelerated Research Therapeutics (START) in San Antonio, TX, a global clinical trial organization enabling first-in-human clinical trials. Before that, Dr. Tolcher was the associated director and director of clinical research at the Cancer Therapy and Research Center (CTRC), UT San Antonio from 1999 to 2007.
Dr. Tolcher received his medical degree from University of British Columbia Faculty of Medicine, internal medicine residency training at the University of Toronto and oncology fellowship at the University of British Columbia, followed with a research fellowship at the National Cancer Institute, Bethesda, Maryland.